Related Experiment Video

Updated: Sep 20, 2026

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis

Oliver Stoeltzing1, Wenbiao Liu, Niels Reinmuth

  • 1Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

Annals of Surgical Oncology
|August 6, 2003
PubMed

Insights

Angiogenesis, the formation of new blood vessels, fuels colorectal cancer growth and spread. Targeting this process with antiangiogenic therapies shows promise for treating metastatic colorectal cancer.

Area of Science:

  • Oncology
  • Cancer Biology
  • Medical Research

Background:

  • Tumor growth and metastasis are critically dependent on angiogenesis.
  • A shift in angiogenic factor balance promotes cancer survival and lesion establishment.
  • Colorectal cancer (CRC) is a major global health concern with significant mortality.

Purpose of the Study:

  • To review the role of angiogenesis in colorectal cancer metastasis.
  • To explore antiangiogenic therapy as a treatment strategy for metastatic CRC.
  • To summarize findings from experimental studies and clinical trials.

Main Methods:

  • Literature review of experimental studies on angiogenesis in CRC metastasis.
  • Analysis of current clinical trial data for antiangiogenic therapies in CRC.
  • Synthesis of evidence on the link between angiogenesis and CRC progression.

Main Results:

  • Angiogenesis is strongly associated with CRC progression and metastatic potential.
  • Inhibiting angiogenesis has demonstrated antineoplastic effects in preclinical models of metastatic CRC.
  • Clinical trials are investigating the efficacy of antiangiogenic agents in CRC patients.

Conclusions:

  • Angiogenesis is a key driver of colorectal cancer metastasis.
  • Targeting angiogenesis represents a promising therapeutic strategy for metastatic CRC.
  • Further clinical investigation is warranted to optimize antiangiogenic treatments for CRC.

More Related Videos

Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones11:43

Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones

Published on: November 30, 2016

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...